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Serum osteoprotegerin (OPG) measurement in Behcet’s disease
Nafiye Fulya İLHAN1, Nesrin DEMİR1, Tamer DEMİR2, Ahmet GÖDEKMERDAN1

Aim: Recent studies indicate that osteoprotegerin (OPG) acts as an important molecule in the development of vascular
diseases. The aim of the present study was to examine the association between serum OPG levels and Behcet’s disease
(BD).
Materials and methods: Twenty-five patients with BD and 20 healthy control subjects, matched for age and sex, were
included in this study. Serum levels of OPG were determined using ELISA.
Results: We found that serum levels of OPG were significantly higher in patients with BD than in healthy control
subjects (813.75 ± 11 vs. 655.56 ± 17 pg/mL, P = 0.002). There was no difference between active patients and those in
remission.
Conclusion: Collectively, serum OPG levels were increased in BD patients, suggesting that OPG might be linked
with the development of vasculitis or other inflammatory processes. It was determined that OPG cannot be used as a
monitoring test by itself; however, it might be a useful marker for supporting clinical and laboratory findings in relation
with BD. Further detailed studies are necessary for a more definitive evaluation of these results.
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Behçet hastalarında serum osteoprotegerin ölçümü
Amaç: Son çalışmalar osteoprotegerinin (OPG) özellikle vasküler hastalıkların gelişiminde önemli bir molekül olduğunu
göstermektedir. Burada sunulan çalışmanın amacı, Behçet hastalığı ile serum osteoprotegerin düzeyleri arasında bir
ilişki olup olmadığını araştırmaktır.
Yöntem ve gereç: 25 Behçet hastası ile cins ve yaş olarak uyumlu 20 sağlıklı kontrol çalışmaya dahil edildi. Serum OPG
düzeyleri ELISA ile değerlendirildi.
Bulgular: Behçetli hastalardaki serum OPG düzeyleri (813,75 ± 11 pg/mL) sağlıklı kontrollerden (655,56 ± 17 pg/mL)
anlamlı olarak yüksek bulundu (P = 0,002). Ancak, aktif dönemdeki hastalarla remisyondakiler arasında OPG düzeyleri
yönünden anlamlı bir fark yoktu.
Sonuç: Behçet hastalarında OPG değerlerinin yüksek bulunması, OPG’nin vaskülitin veya diğer inflamatuar olayların
gelişimiyle ilgili olabileceğini göstermektedir. Sonuç olarak, OPG tek başına hasta izleminde kullanılabilecek bir test
olarak değerlendilmese de Behçet hastalarında klinik ve laboratuar bulguları desteklemek için yararlı bir gösterge
olabilir. Bu sonuçları daha iyi değerlendirmek için detaylı çalışmalara ihtiyaç vardır.
Anahtar sözcükler: Behçet hastalığı, osteoprotegerin
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Introduction

Materials and methods

Osteoprotegerin (OPG) and its ligand (RANKL:
Receptor activator of nuclear factor kappa-lightchain-enhancer of activated B-cells) have key roles
in controlling the orderly development and function
of the immune system. OPG ligand is abundantly
produced by activated T lymphocytes. It prevents
apoptosis and prolongs survival of dendritic cells,
which also express large amounts of the receptor
for OPG ligand (1). Activated T cells are an
important source of OPG ligand, and dendritic
cells are specific targets of the ligand (2). Behcet’s
disease (BD) is an inflammatory vascular disease.
Since vascular diseases are promoted by immunemediated mechanisms, it was hypothesized that OPG
ligand, its antagonist, and OPG, may also form an
important cytokine system in vascular biology. OPG
is an autocrine developmental factor in endothelial
cells (3). Some researchers have found abundant
expression of OPG in the media of the great arteries
and in-vitro analyses revealed OPG production by
arterial smooth-muscle cells and endothelial cells.
These producing areas support its role on the vascular
area. Osteoprotegerin mRNA and protein levels
were very low in endothelial cells plated on the nonintegrin cell attachment; however, osteoprotegerin
mRNA and protein levels were induced 5–7-fold
following αvβ3 ligation by osteopontin. Interestingly,
OPG was upregulated by the binding of αvβ3 integrin
(vitronectin) with osteopontin and was found to
represent an anti-apoptotic signal for endothelial
cells, which suggested an important role for OPG in
maintaining the integrity of the luminal surface of the
vascular wall (4). OPG synthesis was increased with
some cytokines such as TGF-β, TNF-α, IL-1 α, and IL18. Some of these cytokines have a proinflammatory
role (IL-1α, TNF-α,) and stimulatory effect on T cells,
especially Th1 cells (IL-18). BD is strictly related to
T cell stimulation and inflammation; in this respect,
OPG can stimulate inflammatory and cell mediated
immune response related to cytokines. Recent studies
indicate that OPG acts as an important molecule
in the development of different vascular diseases.
The aim of the present study was to examine the
association between serum OPG levels and BD.

This study was approved by the Local Ethical
Committee of Fırat University, Elazığ, Turkey.
Patients were diagnosed with BD according to
the diagnostic criteria of the International Study
Group for BD. Twenty-five BD patients and 20
age- and sex-matched healthy control subjects
were included in this study. Thirteen patients were
in active periods and the remaining 12 patients
were in inactive periods. At the time of the clinical
assessment, patients were included in the active
group if they had at least 2 of the following clinical
findings: oral ulcers, genital ulceration, active uveitis,
recent arthritis, papulopustular or pseudofollicular
cutaneous lesions, neurological involvement, and
pathergy test positivity. Activity criteria: Totally, 18
BD patients had ocular complications (6 with active
ocular attacks, 4 with inflammatory arthritis, and the
rest uveitis with remission period), 7 patients had
mucocutaneous lesions (3 were in the active period
and the rest in remission).

384

Peripheral venous blood samples (2 mL) were
collected in biochemical tubes. Quantitative
measurements of human OPG levels in the serum
were made using RayBiotech, Inc. Human OPG
ELISA kits, according to the manufacturer’s protocol,
on a Dynex 1DXC-1381 (USA) fully automatic
ELISA system. This assay is a sandwich ELISA, using
a biotinylated antihuman OPG for detection. The
plates were read at 450 nm. The minimum detectable
dose of OPG was less than 1 pg/mL.
Statistical analyses were carried using SPSS 11.0
for Windows (SPSS, Inc., Chicago, IL, USA). The
Mann-Whitney U and Kruskal-Wallis tests were
used and a P value of less than 0.05 was considered
statistically significant.
Results
The mean age of the total BD patients (14 females
and 11 males) was 44 years (range: 20-57 years)
and the mean duration of disease was 6.16 years
(range: 1-14 years). Baseline characteristics and
the therapeutic drugs used by patients with BD are
presented in the Table.

N. F. İLHAN, N. DEMİR, T. DEMİR, A. GÖDEKMERDAN

Table. Baseline characteristics of patients with BD.

Patient characteristics

Inactive (n: 13)

Active (n: 12)

36.15

42.25

7.30

9.58

Eye involvement (%)

69.23

41.66

Mucocutaneous lesion (%)

11.38

33.33

Arthritis and musculoskeletal involvement (%)

15.38

25.00

Sumatriptan use (%)

30.76

33.33

Sulfasalazine use (%)

30.76

16.66

Colchicine use (%)

61.53

75.00

Prednisolone use (%)

15.38

25.00

Age (year)
Duration of disease (year)

We found that the serum levels of OPG were
significantly higher in patients with BD compared to
the healthy control subjects (813.75 ± 11 vs 655.56
± 17 pg/mL, P = 0.002). There was no difference
between the active patients and those in remission
(Figure).
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The distribution of osteoprotegerin levels in the patient
and control groups.

Discussion
Recent studies indicate that OPG acts as an
important molecule in the development of vascular
diseases. The major aim of this study was to determine
whether serum measurement of OPG, which can
be easily performed in daily clinical practice, has a
diagnostic or monitoring value in BD patients. The
other aim of the present study was to examine the
association between serum OPG levels and active or
inactive periods of BD patients.
We found that serum levels of OPG were
significantly higher in the patient’s with BD compared
to healthy control subjects (P = 0.002). However, the
levels measured in some healthy controls were similar
to those found in BD patients. Based on our results,
we conclude that the assessment of OPG serum levels
in BD may be of interest from a pathophysiological
point of view; however, its clinical role as a routine
biochemical marker remains questionable.
In one study, it was revealed that OPG levels are
associated with markers of systemic inflammation
in patients with psoriatic arthritis (5). In another
study, 40 patients with systemic lupus erythematosus
(SLE) were evaluated, of whom 20 had active disease.
Osteoprotegerin may have an additional function
due to its ability to bind and inhibit the members of
the tumor necrosis factor (TNF)-superfamily, such
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as TNF-alpha and TNF-related apoptosis inducing
ligand (TRAIL). Mean serum TRAIL concentrations
were elevated in SLE patients, and were higher than in
the healthy control subjects or in other patients with
immune-mediated diseases (rheumatoid arthritis
or Wegener’s granulomatosis) (6). High OPG levels
might be the result of compensatory production
during acute and subacute phases of Kawasaki
disease. Additionally, OPG assay might be a clinically
useful marker to monitor and differentiate patients
who develop such coronary artery abnormalities from
those who do not develop them (7). In another study,
serum OPG levels were increased in SLE patients with
antiphospholipid syndrome (APS) and correlated
with titers of antiphospholipid antibodies, suggesting
that OPG might be linked to the development of APS
(8). There are, however, a number of physiological
effects of OPG that were not discussed and which
demonstrate the depth of influence of the RANK/
RANKL/OPG system on both inflammatory disease
and, possibly, immune surveillance mechanisms.
OPG has a role in mucosal inflammation and it can
be related to mucosal inflammation and oral aft in BD
(9). Recently, the OPG/RANKL/RANK axis has been
implicated in various inflammatory responses and

has also been linked to atherogenesis and peripheral
vascular disease (10). It might be suggested that
OPG may not only have a prominent role in the
vascular or mucosal inflammation associated with
BD, but it could also have considerable significance
in the abnormal immune activation characterizing
BD. Alternatively, elevated OPG in BD may reflect
T-cell activation; however, further functional studies
are necessary to clarify its respective role in BD. We
concluded that OPG levels not only reflect vascular
involvement but also affected uncontrolled systemic
inflammatory situation like other diseases with or
without vasculitis.
Currently, the measurement of OPG levels alone
does not constitute a definitive characteristic test;
however, it might be a useful marker for supporting
clinical and laboratory findings in monitoring BD.
Additional detailed studies are necessary for further
evaluation of these results.
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